Infinity Pharmaceuticals, Inc.（INFIQ）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · INFIQ · 截至 2026-06-09

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2022-12	2021-12	2020-12	2019-12
Revenue
Revenue	$2.59M	$1.86M	$1.72M	$3.05M
Cost of Revenue	$1.56M	$1.12M	$1.04M	$7.31M
Gross Profit	$1.03M	$0.74M	$0.68M	($4.26M)
Gross Margin %(computed)	39.72%	39.72%	39.67%	-139.69%
Operating Expenses
R&D Expenses	$32.41M	$31.65M	$26.76M	$27.12M
G&A Expenses	$13.46M	$14.17M	$12.42M	$14.29M
Total Operating Expenses	$45.87M	$45.82M	$39.18M	$41.41M
Operating Income	($44.84M)	($45.08M)	($38.50M)	($45.66M)
Operating Margin %(computed)	—	—	—	—
Interest Income	$0.00M	$0.00M	$0.00M	$0.00M
Interest Expense	$0.18M	$0.18M	$2.44M	$2.56M
Income Before Tax	($44.37M)	($45.26M)	($40.49M)	($47.11M)
Income Tax Expense	$0.00M	$0.00M	$0.00M	($0.05M)
Net Income	($44.37M)	($45.26M)	($40.49M)	($47.06M)
Net Margin %(computed)	—	—	—	—
Per Share & EBITDA
EPS (Basic)	$-0.50	$-0.53	$-0.68	$-0.83
Wtd Avg Shares	89.25M	85.60M	59.86M	56.98M
EBITDA	($43.73M)	($44.60M)	($37.56M)	($44.33M)
EBITDA Margin %(computed)	—	—	—	—